DE60141773D1 - Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren - Google Patents

Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren

Info

Publication number
DE60141773D1
DE60141773D1 DE60141773T DE60141773T DE60141773D1 DE 60141773 D1 DE60141773 D1 DE 60141773D1 DE 60141773 T DE60141773 T DE 60141773T DE 60141773 T DE60141773 T DE 60141773T DE 60141773 D1 DE60141773 D1 DE 60141773D1
Authority
DE
Germany
Prior art keywords
ligands
use process
similar receptor
great
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60141773T
Other languages
English (en)
Inventor
Alan Aderem
Fumitaka Hayashi
David M Underhill
Adrian Ozinsky
Kelly D Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute for Systems Biology
Original Assignee
Institute for Systems Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23094403&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60141773(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Institute for Systems Biology filed Critical Institute for Systems Biology
Application granted granted Critical
Publication of DE60141773D1 publication Critical patent/DE60141773D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60141773T 2001-04-20 2001-07-20 Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren Expired - Lifetime DE60141773D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28547701P 2001-04-20 2001-04-20
PCT/US2001/022978 WO2002085933A1 (en) 2001-04-20 2001-07-20 Toll-like receptor 5 ligands and methods of use

Publications (1)

Publication Number Publication Date
DE60141773D1 true DE60141773D1 (de) 2010-05-20

Family

ID=23094403

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60141773T Expired - Lifetime DE60141773D1 (de) 2001-04-20 2001-07-20 Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren

Country Status (5)

Country Link
US (3) US7915381B2 (de)
EP (1) EP1379552B2 (de)
AT (1) ATE463505T1 (de)
DE (1) DE60141773D1 (de)
WO (1) WO2002085933A1 (de)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677347B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
EP1379552B2 (de) 2001-04-20 2014-11-19 The Institute for Systems Biology Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren
US8703146B2 (en) 2001-04-20 2014-04-22 Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
US9045727B2 (en) * 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
EP1536832A2 (de) * 2002-09-03 2005-06-08 Fondation Eurovacc Flagellin peptide als adjuvantien für impfstoffe
JP2006519020A (ja) * 2003-02-27 2006-08-24 スリーエム イノベイティブ プロパティズ カンパニー Ｔｌｒ介在生物活性の選択的調節
EP1631687A2 (de) * 2003-04-22 2006-03-08 Coley Pharmaceutical GmbH Verfahren und produkte zur identifizierung und beurteilung von tlr-liganden
EP1617845A4 (de) * 2003-04-28 2006-09-20 3M Innovative Properties Co Zusammensetzungen und verfahren zur induktion von opioid-rezeptoren
JP2007502293A (ja) * 2003-08-12 2007-02-08 スリーエム イノベイティブ プロパティズ カンパニー ヒドロキシルアミン置換イミダゾ含有化合物
EP1658076B1 (de) * 2003-08-27 2013-03-06 3M Innovative Properties Company Aryloxy- und arylalkylenoxy-substituierte imidazochinoline
CA2537763A1 (en) * 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for cd5+ b cell lymphoma
US7544697B2 (en) * 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
US20090075980A1 (en) * 2003-10-03 2009-03-19 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and Analogs Thereof
AR046046A1 (es) * 2003-10-03 2005-11-23 3M Innovative Properties Co Imidazoquinolinas alcoxi sustituidas. composiciones farmaceuticas.
WO2005040208A2 (en) * 2003-10-21 2005-05-06 Androclus Therapeutics, Soa Peptides derived from heat shock proteins binding toll-like receptors 2 and 4 and their use
JP4966661B2 (ja) 2003-10-22 2012-07-04 アイディー バイオメディカル コーポレイション オブ ケベック 生得的免疫およびアレルギー性免疫を活性化させるための組成物および方法
CA2545825A1 (en) * 2003-11-14 2005-06-02 3M Innovative Properties Company Hydroxylamine substituted imidazo ring compounds
CA2545774A1 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Oxime substituted imidazo ring compounds
BRPI0416936A (pt) * 2003-11-25 2007-01-16 3M Innovative Properties Co sistemas de anel de imidazo substituìdos e métodos
EP1701955A1 (de) * 2003-12-29 2006-09-20 3M Innovative Properties Company Arylalkenyl- und arylalkinylsubstituierte imidazochinoline
EP1699788A2 (de) * 2003-12-30 2006-09-13 3M Innovative Properties Company Imidazochinolinyl-, imidazopyridinyl- und imidazonaphthyridinylsulfonamide
KR20050073865A (ko) 2004-01-12 2005-07-18 대한민국(전남대학교총장) 비브리오 패혈증균 편모 구성인자 플라젤린을유효성분으로 함유하는 백신 보조제
AU2005228150A1 (en) * 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
US20080248068A1 (en) * 2004-05-07 2008-10-09 Hans-Gustaf Ljunggren Use of Flagellin as an Adjuvant for Vaccine
DE102004024674A1 (de) * 2004-05-18 2005-12-15 Wolfgang Lorenz Mittel und Verfahren zur Diagnose, Prophylaxe und Therapie von Bindegewebserkrankungen
WO2005123080A2 (en) * 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006009832A1 (en) * 2004-06-18 2006-01-26 3M Innovative Properties Company Substituted imidazo ring systems and methods
WO2006009826A1 (en) * 2004-06-18 2006-01-26 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006065280A2 (en) * 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
WO2006038923A2 (en) * 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
US20090137390A1 (en) * 2004-06-30 2009-05-28 Eric Wendell Triplett Materials and methods for enhancing nitrogen fixation in plants
US20090270443A1 (en) * 2004-09-02 2009-10-29 Doris Stoermer 1-amino imidazo-containing compounds and methods
US7404963B2 (en) * 2004-10-01 2008-07-29 The University Of South Florida Flagellin-based adjuvants and vaccines
WO2006063072A2 (en) * 2004-12-08 2006-06-15 3M Innovative Properties Company Immunomodulatory compositions, combinations and methods
EP1824510B1 (de) * 2004-12-16 2012-10-31 Wake Forest University Health Sciences Verwendung von flagellin bei der immuntherapie von yersinia pestis
EP2460534A1 (de) 2004-12-22 2012-06-06 Cleveland Clinic Foundation Flagellinverwandte Polypeptide und deren Verwendungen
HU227285B1 (en) * 2004-12-29 2011-01-28 Mta Enzimologiai Intezet Modified flagellins and flagellar filaments useful as receptors and processes for producing same
JP5543068B2 (ja) * 2004-12-30 2014-07-09 スリーエム イノベイティブ プロパティズ カンパニー キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
US8034938B2 (en) 2004-12-30 2011-10-11 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
EP1841785A2 (de) 2005-01-19 2007-10-10 Vaxinnate Corporation Zusammensetzungen, die pathogen-assoziierte molekulare muster und antigene enthalten und deren verwendung zur stimulation des immunsystems
US9248127B2 (en) * 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
JPWO2006085411A1 (ja) * 2005-02-10 2008-06-26 国立大学法人 北海道大学 免疫応答を惹起するための新規アジュバントおよびその利用
EP1846405A2 (de) 2005-02-11 2007-10-24 3M Innovative Properties Company Oxim- und hydroxylaminsubstituierte imidazo-4,5-c-ringverbindungen und verfahren
US7700728B2 (en) * 2005-03-24 2010-04-20 Schering Corporation Use of chimeric receptors in a screening assay for identifying agonists and antagonists of cell receptors
CA2602590A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
US7943610B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company Pyrazolopyridine-1,4-diamines and analogs thereof
DE102005020798A1 (de) * 2005-04-28 2006-11-02 Eberhard-Karls-Universität Tübingen Universitätsklinikum Verwendung von TLR- und/oder Nod2-Liganden zur Herstellung eines Arzneimittels zur Behandlung einer Krankheit des zentralen Nervensystems
KR100804507B1 (ko) 2005-05-17 2008-02-20 전남대학교산학협력단 플라젤린을 포함하는 천식 및 알레르기 질환 면역치료제
US8137930B2 (en) * 2005-10-28 2012-03-20 University Of Maryland, Baltimore Attenuated Salmonella enterica serovar paratyphi A and uses thereof
WO2007062043A1 (en) * 2005-11-23 2007-05-31 Coley Pharmaceutical Group Inc. Method of activating murine toll-like receptor 8
WO2007098371A2 (en) * 2006-02-16 2007-08-30 Wayne State University Use of flagellin to prevent and treat gram negative bacterial infection
EP2476432B1 (de) * 2006-03-07 2015-08-19 Vaxinnate Corporation Zusammensetzungen mit Hämagglutinin, Verfahren zu ihrer Herstellung und Verfahren zu ihrer Verwendung
WO2008008432A2 (en) * 2006-07-12 2008-01-17 Coley Pharmaceutical Group, Inc. Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
WO2008063369A2 (en) * 2006-11-01 2008-05-29 George Mason Intellectual Properties, Inc. Biomarkers for neurological conditions
WO2008097016A1 (en) * 2007-02-09 2008-08-14 Chonnam National University Modified flagellin improved toll-like receptor 5 stimulating activity
WO2009079564A2 (en) * 2007-12-17 2009-06-25 Emory University Immunogenic compositions and methods of use thereof
WO2009082440A2 (en) * 2007-12-18 2009-07-02 Vaxinnate Corporation Compositions of toll-like receptor agonists and malaria antigens and methods of use
ES2594102T3 (es) 2008-04-18 2016-12-15 Vaxinnate Corporation Mutantes por deleción de la flagelina y métodos para su uso
WO2010014957A1 (en) 2008-08-01 2010-02-04 Cleveland Biolabs, Inc. Methods for treating reperfusion injuries
EP2349291B1 (de) * 2008-10-03 2012-12-05 Emory University Toll-like-rezeptor-5-agonisten zur behandlung von graft-versus-host-reaktionen
WO2010080007A2 (ko) * 2009-01-09 2010-07-15 부산대학교 산학협력단 Ｔｏｌｌ 유사수용체２ 리간드로서 기능하는 그람양성균 유래의 리포단백질
US9096659B2 (en) 2009-03-18 2015-08-04 Wake Forest University Health Sciences Flagellin fusion proteins and use thereof to induce immune responses against Pseudomonas aeruginosa
WO2010135704A2 (en) * 2009-05-22 2010-11-25 Institute For Systems Biology Secretion-related bacterial proteins for nlrc4 stimulation
WO2010141312A2 (en) 2009-06-01 2010-12-09 Wake Forest University Health Sciences Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
WO2011028875A1 (en) 2009-09-03 2011-03-10 Wake Forest University Health Sciences Immunogenic conjugates for producing immune responses to drugs of abuse and methods of use
US20130108661A1 (en) 2010-02-05 2013-05-02 Mount Sinai School Of Medicine Methods and compositions for cancer immunotherapy using flagellin-tumor associated antigen fusion protein expressing tumor cells
GB2481267B (en) 2010-06-15 2016-04-20 Univ Leicester Assay for determining the risk of a toll-like receptor containing foodstuff for causing systemic inflammation in vivo
US20130150286A1 (en) 2010-06-25 2013-06-13 Jean-Claude Sirard Methods and pharmaceutical compositions for the treatment of respiratory tract infections
WO2012040164A2 (en) 2010-09-24 2012-03-29 Emory University Tlr5 ligands, therapeutic methods, and compositions related thereto
CA2824438A1 (en) 2011-01-10 2012-07-19 Cleveland Biolabs, Inc. Use of toll-like receptor agonist for treating cancer
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
WO2013169382A1 (en) * 2012-05-07 2013-11-14 DePuy Synthes Products, LLC Methods and devices for treating intervertebral disc disease
US9296792B2 (en) 2012-05-23 2016-03-29 The Board Of Trustees Of The Leland Stanford Junior University Ordered flagellin array as an immunostimulant
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
GB201306536D0 (en) * 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
EP3632458A1 (de) 2013-07-26 2020-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Verbindungen und pharmazeutische zusammensetzungen zur behandlung von bakterieninfektionen
CN107087411B (zh) 2014-07-30 2021-06-29 基因组保护股份有限公司 鞭毛蛋白组合物及用途
US10183056B2 (en) 2014-10-16 2019-01-22 Cleveland Biolabs, Inc. Methods and compositions for the treatment of radiation-related disorders
KR102523805B1 (ko) 2014-12-23 2023-04-20 4디 파마 리서치 리미티드 면역 조정
EP3400953A1 (de) 2014-12-23 2018-11-14 4D Pharma Research Limited Pirinpolypeptid und immunmodulation
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
PT3240554T (pt) 2015-06-15 2019-11-04 4D Pharma Res Ltd Blautia stercosis e wexlerae para uso no tratamento de doenças inflamatórias e autoimunes
DK3206700T3 (da) 2015-06-15 2019-08-05 4D Pharma Res Ltd Sammensætninger omfattende bakteriestammer
PT3307288T (pt) 2015-06-15 2019-10-17 4D Pharma Res Ltd Composições compreendendo estirpes bacterianas
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
KR101914245B1 (ko) 2015-11-20 2018-11-02 4디 파마 리서치 리미티드 박테리아성 균주를 함유한 조성물
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
MA42560B1 (fr) 2016-03-04 2019-07-31 4D Pharma Plc Compositions comprenant des souches bactériennes de blautia pour le traitement de l'hypersensibilité viscérale
TW201821093A (zh) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
TW201907928A (zh) 2017-05-22 2019-03-01 英商4D製藥研究有限公司 包含細菌品系之組成物
MA41708A (fr) 2017-05-24 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA49425A (fr) 2017-06-14 2020-04-22 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
ES2841902T3 (es) 2017-06-14 2021-07-12 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
SG11201911430PA (en) * 2017-07-04 2020-01-30 Curevac Ag Novel nucleic acid molecules
EP3668529A4 (de) 2017-07-20 2021-07-14 Spogen Biotech Inc. Bioaktive polypeptide zur verbesserung des pflanzenschutzes, des wachstums und der produktivität
KR102524577B1 (ko) * 2019-04-22 2023-04-21 전남대학교산학협력단 플라젤린 융합 단백질 및 이의 용도
FR3114970B1 (fr) 2020-10-08 2023-06-30 Univ Tours Combinaison d’anticorps inhalés avec des agents immunomodulateurs pour le traitement ou la prévention d’inféctions respiratoires
KR20240027752A (ko) 2021-06-30 2024-03-04 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 플라겔린의 폐 전달을 위한 에어로졸 조성물
KR20240022417A (ko) * 2022-08-10 2024-02-20 주식회사 메디스팬 바실러스 서브틸리스 플라젤린 변이체 및 이의 용도
KR20240055629A (ko) * 2022-10-19 2024-04-29 전남대학교산학협력단 Tlr5 활성능을 가진 플라젤린 면역증강제 유도체의 진핵세포 발현시스템을 이용한 제조 및 응용

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194254A (en) * 1986-05-06 1993-03-16 Connaught Laboratories Limited Enhancement of antigen immunogenicity
US6130082A (en) * 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
US5612035A (en) * 1989-03-21 1997-03-18 The Immune Response Corporation Vaccination against diseases resulting from pathogenic responses by specific T cell populations
US5614192A (en) * 1989-07-19 1997-03-25 Connective Therapeutics, Inc. T cell receptor peptides as therapeutics for immune-related disease
KR0162259B1 (ko) * 1989-12-05 1998-12-01 아미 펙터 감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 키메라 항체
US5618533A (en) * 1992-02-11 1997-04-08 Yale University Flagellin-based polypeptides for the diagnosis of lyme disease
US5888810A (en) * 1993-11-12 1999-03-30 The United States Of America As Represented By The Secretary Of Agriculture Campylobacteri jejuni flagellin-escherichia coli LT-B fusion protein
US5420109A (en) * 1993-11-12 1995-05-30 Houghten Pharmaceuticals, Inc. Cytokine restraining agents
US5817308A (en) * 1994-02-14 1998-10-06 University Of Rochester Tolerogenic fusion proteins of immunoglobulins and methods for inducing and maintaining tolerance
US6190657B1 (en) * 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
US6030624A (en) * 1996-08-16 2000-02-29 Uab Research Foundation Mucosal immunogens for novel vaccines
US6797813B2 (en) * 1996-09-23 2004-09-28 Schering Corporation AK155 antibodies and binding fragments thereof
ATE292980T1 (de) * 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
WO2000023117A1 (en) * 1998-10-16 2000-04-27 The General Hospital Corporation Photosensitizer conjugates for targeting intracellular pathogens
AU5163500A (en) * 1999-05-25 2000-12-12 Immunex Corporation Il-1 eta dna and polypeptides
US6740487B1 (en) * 1999-06-10 2004-05-25 University Of Iowa Research Foundation Variant TLR4 nucleic acid and uses thereof
US7169891B2 (en) * 2000-04-28 2007-01-30 Immunex Corporation Human pellino polypeptides
US20030232055A1 (en) * 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
CN1549726A (zh) * 2000-07-31 2004-11-24 耶鲁大学 先天性免疫系统指导的疫苗
FR2812304B1 (fr) * 2000-07-31 2004-12-17 Bio Merieux Complexe de lipo-viro-particules, procede de preparation et applications
EP1379552B2 (de) 2001-04-20 2014-11-19 The Institute for Systems Biology Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren

Also Published As

Publication number Publication date
US20120269855A1 (en) 2012-10-25
EP1379552B2 (de) 2014-11-19
ATE463505T1 (de) 2010-04-15
EP1379552B1 (de) 2010-04-07
EP1379552A1 (de) 2004-01-14
US20030044429A1 (en) 2003-03-06
US9085616B2 (en) 2015-07-21
WO2002085933A1 (en) 2002-10-31
US20110008318A1 (en) 2011-01-13
US7915381B2 (en) 2011-03-29

Similar Documents

Publication Publication Date Title
DE60141773D1 (de) Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren
MY125202A (en) Vaccine
CY1119291T1 (el) Πολυσθενη αντισωματα και χρησεις για αυτα
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
ATE357930T1 (de) Immunmodulierende zusammensetzungen die eine an antigen gebundene immunstimulierende sequenz enthalten und deren verwendungen
WO2005037190A3 (en) Multiplex vaccines
MXPA04003333A (es) Remodelado y glicoconjugacion de peptidos.
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
EP1594536A4 (de) Adjuvante influenza-vakzine
WO2004030608A3 (en) Nanoemulsion vaccines
NO20063254L (no) Immunstimulerende sammensetning omfattende minst en toll-lignende reseptor 7 eller toll-lignende reseptor 8 agonist og en toll-lignende reseptor 4 agonist
ATE315405T1 (de) Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
MXPA05014016A (es) Proteinas portadoras para vacunas.
NZ508366A (en) Neisseria meningitidis antigens and compositions
CY1112993T1 (el) Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1
DK1353689T3 (da) Immuniseringspræparater og anvendelse deraf
WO2006028429A3 (en) Peptides for targeting the prostate specific membrane antigen
SG167667A1 (en) Nucleic acid compositions for stimulating immune responses
WO2003025119A3 (en) Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies
DE60315827D1 (de) Verbesserte polysaccharid- und glykokonjugat-vakzine
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
AU8727201A (en) Genes involved in intestinal inflammatory diseases and use thereof
WO2005000884A8 (en) Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli
WO2000050073A3 (en) Caulobacter lps immunoadjuvant

Legal Events

Date Code Title Description
8363 Opposition against the patent